Johnson & Johnson (JNJ.US) talquetamab is proposed for priority review in China for inhibiting tumor formation and growth.

On September 24, the CDE website showed that Johnson & Johnson's (JNJ.US) talquetamab (Chinese trade name: Tuolike) is proposed for inclusion in priority review, for use in combination with pomalidomide for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have previously received at least one prior line of therapy (including an anti-CD38 monoclonal antibody and lenalidomide). Talquetamab is a T-cell redirecting bispecific antibody that binds to the CD3 receptor expressed on the surface of T cells and GPRC5D expressed on the surface of multiple myeloma cells. Clinical studies have shown that talquetamab induces killing of GPRC5D-expressing multiple myeloma cells by redirecting T cells, thereby inhibiting tumor formation and growth. The drug was approved for marketing in the United States and the European Union in 2023, and subsequently approved for marketing in China in 2025. The previously approved indication is monotherapy for adult patients with R/R MM who have previously received at least three prior lines of therapy (including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody).